Literature DB >> 23614517

Temporohyoid osteoarthropathy in two young horses.

P K Readford1, G D Lester, C J Secombe.   

Abstract

Two cases of temporohyoid osteoarthropathy (THO) in young Australian horses are described. The pathogenesis of THO is yet to be fully elucidated, but current theories include extension of infection from otitis media or interna to the temporohyoid joint or a primary but non-infectious degenerative condition within the temporohyoid joint. The young age of the horses and the unilateral distribution suggested an infectious aetiology. Both horses partially responded to treatment with broad-spectrum antimicrobial and anti-inflammatory drugs with concurrent management of ulcerative keratitis. The management of violent head shaking in one horse included the administration of gabapentin, an anticonvulsant known to have antihyperalgesic effects and reduce neuropathic pain.
© 2013 The Authors. Australian Veterinary Journal © 2013 Australian Veterinary Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23614517     DOI: 10.1111/avj.12039

Source DB:  PubMed          Journal:  Aust Vet J        ISSN: 0005-0423            Impact factor:   1.281


  3 in total

1.  Neurologic Deficits Including Auditory Loss and Recovery of Function in Horses with Temporohyoid Osteoarthropathy.

Authors:  M Aleman; M Spriet; D C Williams; J E Nieto
Journal:  J Vet Intern Med       Date:  2015-10-29       Impact factor: 3.333

2.  Computed tomography and magnetic resonance imaging findings for the initial stage of equine temporohyoid osteoarthropathy in a Thoroughbred foal.

Authors:  Tomohiro Inui; Kazutaka Yamada; Megumi Itoh; Masashi Yanagawa; Tohru Higuchi; Akiko Watanabe; Yui Imamura; Mako Urabe; Naoki Sasaki
Journal:  J Equine Sci       Date:  2017-09-20

3.  Pharmacokinetics and pharmacodynamics of repeat dosing of gabapentin in adult horses.

Authors:  Jenifer R Gold; Tamara L Grubb; Sherry Cox; Lais Malavasi; Nicholas L Villarino
Journal:  J Vet Intern Med       Date:  2022-02-12       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.